Prosecution Insights
Last updated: July 17, 2026
Application No. 18/292,973

(3-QUINOLYL)-QUINAZOLINE

Non-Final OA §112
Filed
Jan 29, 2024
Priority
Aug 02, 2021 — EU 21189028.0 +1 more
Examiner
JACKSON, SHAWQUIA
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BASF SE
OA Round
1 (Non-Final)
78%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
1419 granted / 1820 resolved
+18.0% vs TC avg
Minimal -3% lift
Without
With
+-3.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
45 currently pending
Career history
1851
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
12.3%
-27.7% vs TC avg
§102
11.0%
-29.0% vs TC avg
§112
62.6%
+22.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1820 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-11 are currently pending in the instant application. Applicants have amended claims 1-11 in amendment filed on January 29, 2024. Claims 1-11 are rejected in this Office Action. I. Priority The instant application is a 371 of PCT/EP2022/070787, filed on July 25, 2022 and claims benefit of Foreign Application EPO 21189028.0, filed on August 2, 2021. II. Information Disclosure Statement The information disclosure statements (IDS) submitted on January 29, 2024 and February 27, 2024 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements have been considered by the examiner. III. Rejections Claim Rejections - 35 USC § 112 The following is a quotation of the second paragraph of 35 U.S.C. 112: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-11 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Specifically, claim 1 contains the definition for variables R1 and R4 as the following “is H, halogen or CN, C1-C4-alkyyl, C1-C4-halogenalkyl”. Applicants have placed an “or” in the middled of the group which makes what Applicants are attempting to claim unclear. It is unclear whether Applicants are attempting to define R1 and R4 as “H, halogen, CN, C1-C4alkyl or C1-C4halogenalkyl or as being selected from two separate groups. For example, R1 is selected from H and halogen or it could be selected from CN, C1-C4alkyl or C1-C4-halogenalkyl. Since it is unclear what Applicants are attempting to claim as their claimed invention with variables R1 and R4, the claims are considered indefinite. Applicants are suggested to amend the claims, for example, so that the definitions of both R1 and R4 read as the following “is selected from the group consisting of H, halogen, CN, C1-C4-alkyl and C1-C4-halogenalkyl” to overcome the above rejection. See MPEP 2173.05(h). IV. Objections Claim Objections Claim 1 is objected to because of the following informalities: claim 1 contains the limitation “and N-oxides and agriculturally acceptable salts thereof” which should read “or an N-oxide or an agriculturally acceptable salt thereof”. Claim1 contains the definition for variable 7a which should have the term “and” in between the terms “phenyl” and “benzyl” and the term “or” between the terms “C2-C6-alkynyl” and “C2-C6-halogenalkynyl”. Appropriate correction is required. ***The closest prior art is JP 2011-148714 A which teaches compounds such as PNG media_image1.png 123 157 media_image1.png Greyscale but does not teach compounds with a quinazoline group substituted on the quinoline ring as seen in the instant compounds PNG media_image2.png 184 363 media_image2.png Greyscale . The above compounds are not taught or suggested by the prior art. V. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shawquia Jackson whose telephone number is 571-272-9043. The examiner can normally be reached on 7:00 AM-3:30PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Adam Milligan can be reached on 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /SHAWQUIA JACKSON/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Jan 29, 2024
Application Filed
Mar 07, 2026
Non-Final Rejection (signed) — §112
May 13, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12668571
SUBSTITUTED 3-AMINO-4-METHYLBENZENESULFONAMIDES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28
3y 4m to grant Granted Jun 30, 2026
Patent 12662458
SOLID FORMS OF A COMPOUND
3y 0m to grant Granted Jun 23, 2026
Patent 12655117
PREPARATION OF SUBSTITUTED AROMATIC CARBOXAMIDES
4y 0m to grant Granted Jun 16, 2026
Patent 12655126
IMIDAZOLE-PYRAZOLE DERIVATIVES AS ANTIBACTERIALS
3y 3m to grant Granted Jun 16, 2026
Patent 12655140
Compound containing structure of a heteroaromatic ring, pharmaceutical composition thereof and application thereof
2y 9m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
78%
Grant Probability
75%
With Interview (-3.4%)
2y 3m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1820 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month